Abstract: The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: The present invention relates generally to the field of microbiology and food sciences. More particularly, the inventor has discovered several polynucleotide sequences encoding the gnd gene and corresponding 6-phosphogluconate dehydrogenase (6-PGD) proteins from different strains of Escherichia Coli and polymorphic sequences therein. Novel biotechnological tools, diagnostics, and food screening techniques are provided.

Abstract: The present invention relates generally to the field of microbiology and food sciences. More particularly, the inventor has discovered several polynucleotide sequences encoding the gnd gene and corresponding 6-phosphogluconate dehydrogenase (6-PGD) proteins from different strains of Escherichia Coli and polymorphic sequences therein. Novel biotechnological tools, diagnostics, and food screening techniques are provided.

Abstract: A method for determining and diagnosing inflammatory enteric disease using an immunochromatographic test device having a multiplicity of test zones. The method tests for the presence of at least one enteric pathogen and at least one of certain inflammatory enteric disease markers. The enteric pathogens tested for can be any number of enteric pathogens such as the pathogens E. coli O157, Campylobacter, Salmonella, Listeria, Shigella, and Yersinia. The inflammatory enteric disease markers tested for are fecal lactoferrin, a bacteria marker, a virus marker, and a protozoa marker. Positive results for any one of the pathogens indicates that pathogen as the cause of the inflammatory enteric disease. Positive results for fecal lactoferrin indicate an inflammatory condition of the intestines. Positive results for the bacteria, virus, protozoa markers indicate respectively a bacterial, viral, or protozoan cause of infection as the cause of the disease.

Abstract: The present invention relates generally to the field of microbiology and food sciences. More particularly, the inventor has discovered several polynucleotide sequences encoding the gnd gene and corresponding 6-phosphogluconate dehydrogenase (6-PGD) proteins from different strains of Escherichia Coli and polymorphic sequences therein. Novel biotechnological tools, diagnostics, and food screening techniques are provided.

Abstract: Polypeptides encoded by a continuous segment of chromosomal DNA from E. coli O157:H7, isolated on plasmid pSC(overlap) (ATCC No. 69648), that encodes an adhesin (SEQ ID NO:5) that mediates bacterial colonization of bovine intestines, vaccines derived therefrom, and antibodies directed against the adhesin.

Abstract: A continuous segment of chromosomal DNA from E. coli O157:H7, isolated on plasmid pSC(overlap) (ATCC No. 69648), encodes an adhesin (SEQ ID NO:4) that mediates bacterial colonization of bovine intestines.

Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions to SEQ ID NO:1 or its complement and to the DNA of enterohemorrhagic E. coli O157:H7 but not to the DNA of enteropathogenic E. coli O55:H7.